Screener
Inhibrx Biosciences, Inc. INBX Business Segments — Gain related to transaction with Acquirer
Similar metrics at other companies
Other financials
Where this comes from
Reported directly by Inhibrx Biosciences, Inc. in its filing.
Tagged under the XBRL concept us-gaap:NonmonetaryTransactionGainLossRecognizedOnTransfer.
The source filing: Inhibrx Biosciences, Inc.’s 10-K, filed March 19, 2026.
- Filed
- Mar 19, 2026, 4:00 PM EDT
- Fiscal year
- FY2025
- Accession
- 0002007919-26-000006
| Line item | YEAR ENDEDDECEMBER 31, 2025 | YEAR ENDEDDECEMBER 31, 2024 |
|---|---|---|
| Total operating expenses | 136,325 | 331,648 |
| Loss from operations | (135,025) | (331,448) |
| Other income (expense): | ||
| Gain related to transaction with Acquirer | — | 2,021,498 |
| Interest expense | (12,196) | (13,491) |
| Interest income | 7,549 | 10,940 |
| Other income (expense), net | (381) | 75 |
| Total other income (expense) | (5,028) | 2,019,022 |
Item 8. Financial Statements and Supplementary Data.
FAQ
- What is Inhibrx Biosciences, Inc.'s business segments — gain related to transaction with acquirer?
- Inhibrx Biosciences, Inc. (INBX) reported business segments — gain related to transaction with acquirer of $0 in Q4 2025.
- How has Inhibrx Biosciences, Inc.'s business segments — gain related to transaction with acquirer changed year-over-year?
- Inhibrx Biosciences, Inc.'s business segments — gain related to transaction with acquirer decreased by 100.0% year-over-year, from $505.37M to $0.
- What does business segments — gain related to transaction with acquirer mean?
- Reflects non-operating financial gains recognized from specific transactions or agreements with an acquiring entity. This metric is essential for identifying non-recurring income that may distort the underlying operational profitability of the segment.
Ask your AI about Inhibrx Biosciences, Inc.'s business segments — gain related to transaction with acquirer.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude